The FDA has accepted a new drug application for Bimatoprost Sustained-Release to reduce IOP in primary open-angle glaucoma or ocular hypertension, Allergan announced.
Data supporting the application from the two phase 3 ARTEMIS trials showed Bimatoprost SR reduced IOP by 30% over 12 weeks, according to a press release. In addition, more than 80% of patients were treatment-free after three Bimatoprost SR treatments and did not require further treatment for IOP control for at least 12 months.
This activity is supported by an educational grant from Aerie Pharmaceuticals, Inc.
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2019 Healio All Rights Reserved.